<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034202</url>
  </required_header>
  <id_info>
    <org_study_id>NN8630-1822</org_study_id>
    <secondary_id>2007-001255-19</secondary_id>
    <nct_id>NCT01034202</nct_id>
  </id_info>
  <brief_title>Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®</brief_title>
  <official_title>A Randomised, Double Blind, Placebo-controlled, Single Dose, Dose-escalating Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin® SimpleXx® in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the safety,
      tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of
      NNC126-0083 compared to Norditropin® SimpleXx® and placebo in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>after administration of a single dose of NNC126-0083</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) (0-168h) after a single dose of NNC 126-0083</measure>
    <time_frame>0-168 hours after trial drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injection site reactions</measure>
    <time_frame>after administration of a single dose of NNC126-0083 and after single dose of Norditropin® SimpleXx®</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-I (Insulin-like Growth Factor I) levels</measure>
    <time_frame>after ascending single doses of NNC126-0083 and a single dose of Norditropin® SimpleXx®</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norditropin® SimpleXx® 0.02 mg/kg + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norditropin® SimpleXx® 0.04 mg/kg + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC126-0083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC126-0083</intervention_name>
    <description>One of five dose levels administered subcutaneously (under the skin)</description>
    <arm_group_label>Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083</arm_group_label>
    <arm_group_label>Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norditropin® SimpleXx®</intervention_name>
    <description>One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)</description>
    <arm_group_label>Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083</arm_group_label>
    <arm_group_label>Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Norditropin® SimpleXx® 0.02 mg/kg + placebo</arm_group_label>
    <arm_group_label>Norditropin® SimpleXx® 0.04 mg/kg + placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC126-0083</intervention_name>
    <description>One of three dose levels administered subcutaneously (under the skin)</description>
    <arm_group_label>NNC126-0083</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norditropin® SimpleXx®</intervention_name>
    <description>One of two dose levels, followed by placebo, administered subcutaneously (under the skin)</description>
    <arm_group_label>Norditropin® SimpleXx® 0.02 mg/kg + placebo</arm_group_label>
    <arm_group_label>Norditropin® SimpleXx® 0.04 mg/kg + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking male subjects

          -  Body Mass Index (BMI) between 19.0 and 28.0 kg/m2, both inclusive

          -  Body weight max. 100 kg

        Exclusion Criteria:

          -  A history or presence of cancer, diabetes, or any clinically significant
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal,
             endocrinological, haematological, dermatological, venereal, neurological, psychiatric
             diseases or other major diseases

          -  Carrier of Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies

          -  Positive result of test for HIV (Human Immunodeficiency Virus) antibodies

          -  Any clinically significant abnormal haematology or biochemistry screening tests, as
             judged by the physician

          -  Clinically significant abnormal ECG (ElectroCardioGram) at screening as evaluated by
             the physician

          -  A significant history of alcoholism or drug/chemical abuse, or who has a positive
             result in the urine drug/alcohol screen, or who consumes more than 28 units of alcohol
             per week (one unit of alcohol equals about 250 ml of beer or lager, 1 glass of wine,
             or 20 ml of spirits)

          -  Habitual smoking, i.e daily smoking or more than 7 cigarettes/week

          -  Mental incapacity or language barriers which preclude adequate understanding or
             cooperation, who are unwilling to participate in the trial, or who in the opinion of
             their general practitioner or the Investigator should not participate in the trial

          -  Surgery or trauma with significant blood loss within the last 2 months prior to dosing
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T, Madsen J. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J Clin Endocrinol Metab. 2010 Jul;95(7):3411-7. doi: 10.1210/jc.2009-2813. Epub 2010 Apr 28.</citation>
    <PMID>20427496</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

